GlassScriptPhysician profile
Andrew Shakespeare
NPI 1184068363
$15,449.81
in general payments reported to CMS, 2019-2025
36 companies · $1,663 in 2025
The $1,663 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $1,165 · 2021: $1,555 · 2022: $1,702 · 2023: $1,771 · 2024: $7,082 · 2025: $1,663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,411 · Travel and Lodging: $2,606 · Education: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,410.57 |
| Travel and Lodging | $2,605.60 |
| Education | $2,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,161.68 | 2024 | |
| Glaxosmithkline, LLC. | $3,243.89 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,299.39 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Astrazeneca Pharmaceuticals LP | $1,063.56 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Grifols USA, LLC | $733.62 | 2019-2025 | Prolastin-C Liquid |
| Amgen INC. | $509.99 | 2022-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $309.50 | 2019-2024 | Opsumit |
| Baxter Healthcare | $302.73 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Takeda Pharmaceuticals U.S.A., INC. | $282.11 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $263.16 | 2019-2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $253.18 | 2021-2023 | Xarelto |
| Insmed, INC. | $238.18 | 2019-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $225.97 | 2020-2024 | Yupelri |
| Verona Pharma, INC. | $175.73 | 2025 | Ohtuvayre |
| Genzyme Corporation | $165.50 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $146.96 | 2019-2024 | Keytruda, Winrevair |
| Pfizer INC. | $141.06 | 2023-2025 | |
| Abbvie INC. | $140.26 | 2021-2025 | |
| Abiomed | $124.68 | 2024 | Impella |
| United Therapeutics Corporation | $76.53 | 2021-2023 | Tyvaso |
| Mallinckrodt Hospital Products INC. | $65.75 | 2020-2024 | Terlivaz |
| Philips North America LLC | $61.74 | 2021-2023 | |
| Genentech USA, INC. | $54.54 | 2020-2024 | Xolair |
| Harmony Biosciences LLC | $51.20 | 2022 | |
| Electromed, INC. | $48.60 | 2019-2025 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $45.88 | 2020-2025 | |
| Sanofi US Services INC. | $41.46 | 2025 | |
| Inogen, INC. | $38.22 | 2022-2025 | |
| Shire North American Group INC | $33.69 | 2019 | |
| Viatris Specialty LLC | $32.07 | 2025 | Yupelri |
| Allergan, INC. | $26.56 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $24.61 | 2022 | |
| Gilead Sciences, INC. | $17.97 | 2021 | |
| Advanced Respiratory, INC | $17.79 | 2021 | |
| Mallinckrodt Enterprises LLC | $17.29 | 2019 | |
| Chiesi USA, INC. | $14.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Shakespeare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.